Patent
أعرض في EDS

Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

التفاصيل البيبلوغرافية
العنوان: Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
Patent Number: 9,272,990
تاريخ النشر: March 01, 2016
Appl. No: 13/992053
Application Filed: December 06, 2011
مستخلص: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
Inventors: Seiders, Thomas Jon (San Diego, CA, US); Wang, Bowei (Westfield, NJ, US); Hutchinson, John Howard (San Diego, CA, US); Stock, Nicholas Simon (Encinitas, CA, US); Volkots, Deborah (New York, NY, US)
Assignees: AMIRA PHARMACEUTICALS, INC. (Princeton, NJ, US)
Claim: 1. The compound of Formula (II): [chemical expression included] wherein: R 1 is —CO 2 H, —CO 2 R D , —C(═O)NHSO 2 R 10 , —C(═O)N(R 9) 2 , —C(═O)NH—OH, —C(═O)NH—CN, —P(═O)(OH) 2 , —P(═O)(OR D) 2 , —OPO 3 H 2 , —SO 2 NHC(═O)R 10 , —CN, —C(═NH)—NH 2 , —C(═NH)—NHC(═O)R D , —C(═O)NHCH 2 CH 2 SO 3 H, tetrazolyl, 5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl, or carboxylic acid bioisostere; R D is H or C 1 -C 6 alkyl; L 2 is a substituted or unsubstituted C 1 -C 6 alkylene, substituted or unsubstituted C 1 -C 6 fluoroalkylene, or substituted or unsubstituted C 1 -C 6 heteroalkylene, where if L 2 is substituted then L 2 is substituted with 1, 2 or 3 R 12 ; each R 12 is independently F, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, hydroxyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy or a substituted or unsubstituted phenyl; or L 2 is -L 3 -X 1 -L 4 -; L 3 is absent or a substituted or unsubstituted C 1 -C 4 alkylene, where if L 3 is substituted then L 3 is substituted with 1, 2, or 3 R 13 ; each R 13 is independently F, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, hydroxyl, C 1 -C 4 alkoxy or C 1 -C 4 fluoroalkoxy; X 1 is absent, —O—, —S—, —S(O)—, —S(O) 2 —, —NR 7 —, —C(O)NR 8 —, —NR 8 C(═O)—, —NR 8 C(═O)CH 2 O—, —NR 8 C(═O)—CH(CH 3)O—, —NR 8 C(═O)—C(CH 3) 2 O—, —N(R 8)S(═O) 2 —, —S(═O) 2 N(R 8)—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —OC(═O)N(R 8)—, —NR 8 C(═O)O—, or —NR 8 C(═O)N(R 8)—; R 7 is H, —S(═O) 2 R 16 , —S(═O) 2 N(R 9) 2 , —C(═O)R 10 , —CO 2 R 9 , —C(═O)N(R 9) 2 , C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, or C 1 -C 4 heteroalkyl; R 8 is H, C 1 -C 4 alkyl, or C 1 -C 4 fluoroalkyl; L 4 is absent or a substituted or unsubstituted C 1 -C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1, 2, or 3 R 14 ; each R 14 is independently F, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, hydroxyl, C 1 -C 4 alkoxy or C 1 -C 4 fluoroalkoxy; or L 2 is -L 5 -X 2 -L 6 -; L 5 is absent, —C(═O)—, —S—, —S(O)—, —S(O) 2 —, —N(R D)—, —N(R D)C(═O)—, substituted or unsubstituted C 1 -C 4 alkylene, substituted or unsubstituted C 1 -C 4 fluoroalkylene, or a substituted or unsubstituted C 1 -C 4 heteroalkylene, where if L 5 is substituted, then L 5 is substituted with 1 or 2 R 15 , where each R 15 is F, C 1 -C 4 alkyl, —OH, —OR 8 , or —N(R 8) 2 ; X 2 is a substituted or unsubstituted cyclic group selected from a substituted or unsubstituted C 3 -C 6 cycloalkylene, a substituted or unsubstituted C 2 -C 5 heterocycloalkylene, a substituted or unsubstituted monocyclic C 1 -C 5 heteroarylene, and a substituted or unsubstituted phenylene, where if X 2 is substituted, then X 2 is substituted with 1 or 2 R 17 , each R 17 is independently halogen, —CN, —OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, C 1 -C 4 alkoxy, or C 1 -C 4 heteroalkyl; L 6 is absent, a substituted or unsubstituted C 1 -C 4 alkylene, substituted or unsubstituted C 1 -C 4 fluoroalkylene, substituted or unsubstituted C 1 -C 4 heteroalkylene, —O—, —S—, —S(O)—, SO 2 , N(R 8)—, or —C(═O)—N(R 8)—C 1 -C 4 alkylene-, where if L 6 is substituted, then L 6 is substituted with 1 or 2 R 16 , where each R 16 is independently F, C 1 -C 4 alkyl, —OH, —OR 8 , or —N(R 8) 2 ; R A and R B are independently halogen, —CN, —OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, or C 3 -C 6 cycloalkyl; Each R c is independently halogen, —OH, —CH 3 , —CH 2 CH 3 , —CF 3 , —OCF 3 , —OCH 3 and —OCH 2 CH 3 ; A is phenyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl pyridazinyl, thiophenyl, isoquinolinyl, or thiadiazolyl; R 3 is H or C 1 to C 4 alkyl; each R 9 is independently H, C 1 -C 6 heteroalkyl, C 1 -C 6 fluoroalkyl, a substituted or unsubstituted C 3 -C 10 cycloalkyl, a substituted or unsubstituted C 2 -C 10 heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted —C 1 -C 4 alkylene-C 3 -C 10 cycloalkyl, a substituted or unsubstituted —C 1 -C 4 alkylene-C 2 -C 10 heterocycloalkyl, a substituted or unsubstituted —C 1 -C 4 alkylene-aryl, or a substituted or unsubstituted —C 1 -C 4 alkylene-heteroaryl; or two R 9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle; R 10 is C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 fluoroalkyl, a substituted or unsubstituted C 3 -C 10 cycloalkyl, a substituted or unsubstituted C 2 -C 10 heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted —C 1 -C 4 alkylene-C 3 -C 10 cycloalkyl, a substituted or unsubstituted —C 1 -C 4 alkylene-C 2 -C 10 heterocycloalkyl, a substituted or unsubstituted —C 1 -C 4 alkylene-aryl, or a substituted or unsubstituted —C 1 -C 4 alkylene-heteroaryl; m is 0, 1, or 2; n is 0, 1, or 2; and p is 0, 1, or 2.
Claim: 2. The compound of claim 1 wherein: L 2 is a substituted or unsubstituted C 3 -C 6 alkylene, substituted or unsubstituted C 3 -C 6 fluoroalkylene, or substituted or unsubstituted C 3 -C 6 heteroalkylene, where if L 2 is substituted then L 2 is substituted with 1, 2 or 3 R 12 , each R 12 is independently selected from F, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, hydroxyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy and phenyl.
Claim: 3. The compound of claim 1 , wherein: L 2 is —CH(OH)CH 2 CH 2 CH 2 —, —CH(OH)CF 2 CH 2 CH 2 —, —CH(OH)CH 2 OCH 2 —, —CH(OH)CH 2 SCH 2 —, —NHCH(CH 3)CH 2 CH 2 —, —NH(CO)O—CH(CH 3)—, —NH(pyridine-2,6,diyl)-, —CH(OH)-(triazol01,4-diyl)-CH 2 , or —NHCH 2 -(thiazol-2,5-diyl)-.
Claim: 4. The compound of claim 1 wherein: L 2 is -L 3 -X 1 -L 4 -; L 3 is absent or a substituted or unsubstituted C 1 -C 4 alkylene, where if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 ; each R 13 is independently selected from F, —CH 3 , —CH 2 CH 3 , —CF 3 , hydroxyl, —OCH 3 , —OCH 2 CH 3 , and —OCF 3 ; X 1 is —O—, —S—, —S(O)—, —S(O) 2 —, —NR 7 —, —C(O)NR 8 —, —NR 8 C(═O)—, —NR 8 C(═O)CH 2 O—, —NR 8 C(═O)— —CH(CH 3)O—, —NR 8 C(═O)—C(CH 3) 2 O—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —OC(═O)N(R 8)—, —NR 8 C(═O)O—, or —NR 8 C(═O)N(R 8)—; R 7 is H, —C(═O)R 10 , or —C 1 -C 4 alkyl; R 8 is H, or C 1 -C 4 alkyl; L 4 is absent or a substituted or unsubstituted C 1 -C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 , each R 14 is independently selected from F, —CH 3 , —CH 2 CH 3 , —CF 3 , hydroxyl, —OCH 3 , —OCH 2 CH 3 , and —OCF 3 .
Claim: 5. The compound of claim 1 , wherein: L 2 is -L 5 -X 2 -L 6 -; L 5 is absent, —C(═O)—, —S—, —S(O)—, —S(O) 2 —, —N(R D)—, substituted or unsubstituted C 1 -C 4 alkylene, and substituted or unsubstituted C 1 -C 4 heteroalkylene, where if L 5 is substituted, then L 5 is substituted with R 15 , where R 15 is F, —CH 3 , —CH 2 CH 3 , —OH, —OCH 3 , or —OCH 2 CH 3 ; L 6 is absent, a substituted or unsubstituted C 1 -C 4 alkylene, substituted or unsubstituted C 1 -C 4 heteroalkylene, —O—, —S—, —S(O)—, SO 2 , —N(R D)—, or —C(═O)—N(R D)—C 1 -C 4 alkylene-, where if L 6 is substituted, then L 6 is substituted with R 16 , where each R 16 is F, C 1 -C 4 alkyl, —OH, —OR D , or —N(R D) 2 ; X 2 substituted or unsubstituted thiazolylene, substituted or unsubstituted triazolylene, substituted or unsubstituted pyridinylene, where if X 2 is substituted, then X 2 is substituted with R 16 , where R 16 is halogen, —CN, —OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, or C 1 -C 4 alkoxy.
Claim: 6. The compound of claim 1 , wherein the compound is: 1-(4′-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-pyridin-3-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid; 1-[2″-((R)-1-Phenyl-ethoxycarbonylamino)-[1,1′;4′,1″]terphenyl-4-yl]-cyclopropanecarboxylic acid; 1-{4′-[3-((R)-1-Phenyl-ethoxycarbonylamino)-pyridin-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[4-((R)-1-Phenyl-ethoxycarbonylamino)-oxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-pyridin-2-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[2-(1-Hydroxy-4-phenyl-butyl)-thiophen-3-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[2-(1-Hydroxy-4-phenyl-butyl)-[1,1′;4′,1″]terphenyl-4″-yl]-cyclopropanecarboxylic acid; (1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-pyridin-4-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; 1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-pyridin-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; (1-{4′-[5-(1-Hydroxy-4-phenyl-butyl)-1-methyl-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; 1-{4′-[5-(1-Hydroxy-4-phenyl-butyl)-1-methyl-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; (1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-pyridin-2-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; (1-{4′-[2-(1-Hydroxy-4-phenyl-butyl)-thiophen-3-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; (1-{4′-[4-(1-Hydroxy-4-phenyl-butyl)-thiophen-3-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; 1-{4′-[4-(1-Hydroxy-4-phenyl-butyl)-thiophen-3-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[4-(1-Hydroxy-4-phenyl-butyl)-isoquinolin-3-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[4-(1-Hydroxy-4-phenyl-butyl)-pyridin-3-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-thiophen-2-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; (1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-thiophen-2-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; 1-{4′-[1-Methyl-5-(6-phenyl-pyridin-2-ylamino)-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-(4′-{5-[3-(4-Chloro-phenyl)-1-methyl-propylamino]-1-methyl-1H-pyrazol-4-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid; 1-(4′-{5-[(1-Benzyl-1H-[1,2,3]triazol-4-yl)-hydroxy-methyl]-1-methyl-1H-pyrazol-4-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid; 1-{4′-[1-Ethyl-5-(1-hydroxy-4-phenyl-butyl)-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; (1-{4′-[1-Ethyl-5-(1-hydroxy-4-phenyl-butyl)-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid; 1-(4′-{1-Methyl-[(2-phenyl-thiazol-5-ylmethyl)-amino]-1H-pyrazol-4-yl}-bi-phenyl-4-yl)-cyclopropanecarboxylic acid; 1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-thiophen-2-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-{4′-[3-(1-Hydroxy-4-phenyl-butyl)-thiophen-2-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; or a pharmaceutically acceptable salt of any of the preceding compounds.
Claim: 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
Patent References Cited: 2005/0245543 November 2005 Howard et al.
2012/0196839 August 2012 Hutchinson et al.
2013/0253023 September 2013 Brittain et al.
0730019 September 1996
1371712 December 2003
1156997 November 2004
1970362 September 2008
60239743 November 1985
61037885 February 1986
2007169363 July 2007
2010209042 September 2010
WO 02/089738 November 2002
WO 2011/041694 April 2011
WO 2011/159550 December 2011
WO 2011/159633 December 2011
Other References: Barzoukas et al., Chemical Physics, vol. 185, No. 1, pp. 65-74 (1994). cited by applicant
Bezborodov, et al., Liquid Crystals: an International Journal of Science and Technology, vol. 28, No. 6, pp. 897-900 (2001). cited by applicant
Campbell et al., Journal of the American Chemical Society, vol. 82, No. 12, pp. 3126-3128 (1960). cited by applicant
Chen et al., Molecular Cancer Therapeutics, vol. 4, No. 6, pp. 1019-1025 (2005). cited by applicant
Chen et al., Macromolecules, vol. 42, No. 14, pp. 5053-5061 (2009). cited by applicant
Koch et al., Journal of Physical Organic Chemistry, vol. 21, No. 11, pp. 954-962 (2008). cited by applicant
Koch et al., Journal of Physical Organic Chemistry, pp. 1-47 (2008). cited by applicant
Ming So et al., Chemistry—A European Journal, vol. 16, No. 27, pp. 7996-8001 (2010). cited by applicant
Puccetti et al., Chemical Physics, pp. 467-475 (1992). cited by applicant
Sadashiva et al., Molecular Crystals and Liquid Crystals, vol. 38, pp. 345-352 (1977). cited by applicant
Sahara et al., Liquid Crystals: an International Journal of Science and Technology, vol. 19, No. 2, pp. 207-211 (1995). cited by applicant
Sakaguchi et al., Polymer Journal, Society of Polymer Science, vol. 33, No. 9, pp. 654-661 (2001). cited by applicant
Schiek et al., Synthesis, No. 4, pp. 613-621 (2007). cited by applicant
Swaney et al., British Journal of Pharmacology, vol. 160, No. 7, pp. 1699-1713 (2010). cited by applicant
Takatsua et al., Molecular Crystals and Liquid Crystals Science and Technology, vol. 364, No. 1, pp. 171-186 (2001). cited by applicant
Bezborodov et al., Liquid Crystals: an International Journal of Science and Technology, vol. 28, No. 6, pp. 897-900 (2001). cited by applicant
Bezborodov et al., “From 3,6-disubstituted cyclohex-2-enones to advanced FLC compounds”, Ferroelectrics, vol. 343, pp. 49-58 (2006). cited by applicant
Assistant Examiner: Javanmard, Sahar
Primary Examiner: Padmanabhan, Sreeni
Attorney, Agent or Firm: Hoffmann & Baron, LLP
رقم الانضمام: edspgr.09272990
قاعدة البيانات: USPTO Patent Grants
الوصف
الوصف غير متاح.